Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 17/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.61 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1889178 | 0.86 | PIK3CG (0.64) | PIK3CGPIK3CAPIK3CDPIK3CBATAD2 | |
| SCHEMBL12002638 | 0.85 | PIK3CG (0.66) | PIK3CGPIK3CAPIK3CDPIK3CB | |
| SCHEMBL12992093 | 0.84 | PIK3CG (0.74) | PIK3CGPIK3CAPIK3CDPIK3CBXIAP | |
| SCHEMBL12991601 | 0.83 | PIK3CG (0.56) | PIK3CGPIK3CAATAD2CYP1A2 | |
| SCHEMBL10670937 | 0.83 | PIK3CG (0.72) | PIK3CGPIK3CAPIK3CDPIK3CBXIAP | |
| SCHEMBL14364244 | 0.83 | KDM4E (0.55) | PIK3CGPIK3CAPIK3CDPIK3CBATAD2 | |
| SCHEMBL6545803 | 0.83 | ADORA3 (0.67) | PIK3CGPIK3CAATAD2 | |
| SCHEMBL10667929 | 0.83 | PIK3CG (0.52) | PIK3CGPIK3CAPIK3CDPIK3CBATAD2 | |
| SCHEMBL5051369 | 0.82 | GAA (0.59) | PIK3CGPIK3CAATAD2XIAPCYP1A2 | |
| SCHEMBL6546496 | 0.82 | ALDH1A1 (0.66) | PIK3CGPIK3CAATAD2XIAPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344153-B2 | Inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144513-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-16 | — | — | WO | disclosed |
| EP-0280873-A1 | Piperidines, medicines containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316605-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CG, PIK3CD | PIK3CG 2/4885PIK3CA 1/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.